General and administrative expenses for the quarter ended March 31, 2011 totaled $1,174,000 as compared to $699,000 during the quarter ended March 31, 2010.
Upcoming Communications/Special Meeting of Shareholders
Cardiogenesis will not be hosting an investor conference call associated with the first quarter results and the filing of its Report on Form 10-Q with the SEC for the quarter ended March 31, 2011. Cardiogenesis will be holding a special meeting of its shareholders, which will be held at 8:30 a.m., Pacific, on Monday, May 16, 2011. At the special meeting of shareholders, Cardiogenesis' shareholders will vote on the proposal to approve and adopt Cardiogenesis' Agreement and Plan of Merger with CryoLife, Inc. and CL Falcon, Inc., a wholly-owned subsidiary of CryoLife. If the proposal to adopt the merger agreement is approved by the requisite number of holders of Cardiogenesis' common stock, Cardiogenesis anticipates that the closing of the merger will occur before the end of its second fiscal quarter. Cardiogenesis' shareholders are encouraged to read the definitive proxy statement relating to the merger in its entirety as it provides, among other things, a detailed discussion of the process that led to execution of the merger agreement.
About Cardiogenesis Corporation
Cardiogenesis specializes in the treatment of cardiovascular disease and is a leader in devices that treat severe angina. Our market leading holmium:YAG laser system and single use fiber-optic delivery systems are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR).
For more information on Cardiogenesis and its products, please visit our website at www.cardiogenesis.com.
|SOURCE Cardiogenesis Corporation|
Copyright©2010 PR Newswire.
All rights reserved